NCT06276010 Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO
| NCT ID | NCT06276010 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xiaotong Hou |
| Condition | Extracorporeal Membrane Oxygenation Complication |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-07-01 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years old 2. VA-ECMO or VV-ECMO was accepted after cardiac surgery. 3. The ECMO treatment team believes that systemic anticoagulation is needed 4. Sign the informed consent form Exclusion Criteria: 1. The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study. 2. Long-term use of anticoagulants before establishment of ECMO 3. Antiplatelet drugs were used before the establishment of ECMO 4. Severe liver insufficiency 5. Connective tissue disease 6. There is a history of allergy to heparin or nemolastat mesylate. 7. Pregnant 8. Previous diagnosis of heparin-induced thrombocytopenia 9. Expect to die within 48 hours 10. ECPR
Contact & Investigator
Zhongtao Du, MD
STUDY CHAIR
Beijing Anzhen Hospital
Frequently Asked Questions
Who can join the NCT06276010 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Extracorporeal Membrane Oxygenation Complication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06276010 currently recruiting?
Yes, NCT06276010 is actively recruiting participants. Contact the research team at xt.hou@ccmu.edu.cn for enrollment information.
Where is the NCT06276010 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06276010 clinical trial?
NCT06276010 is sponsored by Xiaotong Hou. The principal investigator is Zhongtao Du, MD at Beijing Anzhen Hospital. The trial plans to enroll 80 participants.